Australian University Rankings Guide

Assay and Drug Development Technologies (ERA Journal)

Assay and Drug Development Technologies is an ERA accredited research journal used as part of the evaluation of the ERA research rankings.

Assay and Drug Development Technologies issns are issn1: 1540-658X issn2: 1557-8127.

The fields covered by Assay and Drug Development Technologies as part of the evaluation of Australian university research excellence are:

Medicinal and Biomolecular Chemistry Research Rankings (Sub-Field)

Physical Chemistry (Incl. Structural) Research Rankings (Sub-Field)

Pharmacology and Pharmaceutical Sciences Research Rankings (Sub-Field)

Other ERA-accredited journals supporting the evaluation of the Medicinal and Biomolecular Chemistry field include:

- ARKIVOC
- Annual Reports in Medicinal Chemistry
- Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry
- Archiv der Pharmazie
- Biocatalysis and Biotransformation
- Biochemical and Biophysical Research Communications
- Chemical Research in Toxicology
- Current Protein and Peptide Science
- Evolutionary Applications: evolutionary approaches to environmental biomedical and socio-economic issues
- Journal of Biological Inorganic Chemistry
- Journal of Cellular and Molecular Medicine
- Journal of Molecular Biology
- Journal of Toxicology
- Organic Preparations and Procedures International: the new journal for organic synthesis
- Vibrational Spectroscopy


ERA Research Rankings Submenu


- ERA 2018 Outcomes Research Rankings List

- ERA 2018 Research Rankings Analysis

- ERA 2018 Individual University Outcomes List

- ERA List of Research Fields Rankings

- ERA Journal Rankings 2018 List



Latest News and Updates:


- Top 10 Best Australian Universities

- Gender Balance Male-Female Ratio

- ERA 2018 Outcomes Research Rankings List

- University Bachelor Degree Completion Rates

- QS Employability Rankings Australian Universities

- ARWU World Rankings of Australian Universities

- Group of Eight (go8) World Rankings

Share This Page

  • Share on Facebook1
  • Share on Twitter2
  • Share on Linkedin3
  • Share on Reddit4